GSK: Please, EMA, Can We Have Some More?
Company Is Seeking Another Speedy Review
Hot on the heels of winning EU fast-track review status for belantamab mafodotin, GlaxoSmithKline has asked the European Medicines Agency to grant accelerated assessment to another of its planned marketing applications.